SPRO vs. TRVI, CKPT, CLSD, LPTX, BIVI, ACRS, KRON, AFMD, ELYM, and PYXS
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Trevi Therapeutics (TRVI), Checkpoint Therapeutics (CKPT), Clearside Biomedical (CLSD), Leap Therapeutics (LPTX), BioVie (BIVI), Aclaris Therapeutics (ACRS), Kronos Bio (KRON), Affimed (AFMD), Eliem Therapeutics (ELYM), and Pyxis Oncology (PYXS). These companies are all part of the "medical" sector.
Trevi Therapeutics (NASDAQ:TRVI) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
76.3% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 27.3% of Spero Therapeutics shares are owned by institutional investors. 27.5% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Trevi Therapeutics has a net margin of 0.00% compared to Trevi Therapeutics' net margin of -2.08%. Trevi Therapeutics' return on equity of 4.14% beat Spero Therapeutics' return on equity.
Trevi Therapeutics has higher earnings, but lower revenue than Spero Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
In the previous week, Trevi Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Trevi Therapeutics and 0 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.58 beat Trevi Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Spero Therapeutics received 123 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 68.88% of users gave Spero Therapeutics an outperform vote while only 59.68% of users gave Trevi Therapeutics an outperform vote.
Trevi Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 503.45%. Spero Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 451.18%. Given Spero Therapeutics' higher probable upside, equities analysts clearly believe Trevi Therapeutics is more favorable than Spero Therapeutics.
Summary
Trevi Therapeutics and Spero Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Spero Therapeutics Competitors List
Related Companies and Tools